Patent ID: 11866742
Assignee: DENALI THERAPEUTICS INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 14:
15. A method of treating Hunter syndrome in a subject in need thereof, comprising administering to the subject a protein comprising:
a. a fusion polypeptide comprising a first Fc polypeptide linked to an iduronate 2-sulfatase (IDS) amino acid sequence, wherein the fusion polypeptide comprises SEQ ID NO: 235; and
b. a second Fc polypeptide comprising a sequence having at least 90% identity to SEQ ID NO: 151 and having at the following positions with reference to SEQ ID NO: 151:
i. Trp, Leu, or Glu at position 150;
ii. Tyr at position 154;
iii. Thr at position 156;
iv. Glu at position 157;
v. Trp at position 158;
vi. Ser or Ala at position 159;
vii. Ser or Asn at position 160;
viii. Thr at position 183;
ix. Glu at position 185;
x. Glu at position 186; and
xi. Phe at position 191.